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Rho-associated kinases (ROCK) are activated in the kidney as
well as in cultured cells of diabetic models and have been
implicated in renal pathophysiology. To explore whether
inhibition of ROCK is protective, we studied its role in
a model of accelerated diabetic nephropathy where
uninephrectomized rats were made diabetic by
streptozotocin. After establishing diabetes, rats were treated
with the ROCK inhibitor fasudil continuously or for the
final 6 weeks of an 18-week experimental period. The results
were compared to similar rats given losartan, an established
treatment of clinical and experimental diabetic nephropathy,
or a combination of both agents. Vehicle-treated diabetic
and non-diabetic uninephrectomized rats served as controls.
Diabetes resulted in a rapid development of albuminuria,
higher glomerulosclerosis and interstitial fibrosis scores,
lower glomerular filtration rates, and increased expression
of several molecular markers of diabetic nephropathy.
Eighteen weeks of fasudil treatment reduced renal ROCK
activity, and ameliorated diabetes-induced structural changes
in the kidney and expression of the molecular markers
in association with a modest anti-proteinuric effect but
no change in blood pressure. Late intervention with
fasudil reduced glomerulosclerosis, but did not influence
proteinuria. Most effects of fasudil were comparable to
those of losartan, although losartan lowered blood pressure
and further lowered proteinuria. The combination of
both treatments was no different than losartan alone.
Thus, ROCK inhibition protected the kidney from diabetic
nephropathy even though it did not reduce the blood
pressure.
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Despite progress in the prevention and treatment of diabetic
nephropathy (DN), reversal and even stabilization of the
progressive course of DN are still difficult to achieve, and
many patients still progress to end-stage renal disease. New
approaches that would broaden the spectrum of available
treatments for DN are needed to improve prognosis in these
patients.
RhoA, a member of the Ras superfamily of small
GTP-binding proteins, and its downstream effectors
Rho-associated kinases (ROCKs), are signaling molecules
implicated in a variety of biological functions, including cell
contraction, cell migration, cell adhesion, cell cycle progres-
sion, and gene expression.1 The RhoA/ROCK pathway is
stimulated by agonists acting via G-protein-coupled, tyrosine
kinase, and cytokine receptors, cell adhesion and integrin
clustering, as well as by mechanical stress, which regulate the
activity of RhoA guanine nucleotide exchange factors and
GTP loading of RhoA.1 RhoA/ROCK have emerged
as important players in cardiovascular and renal patho-
physiology. This pathway is activated in the vasculature and
kidney in different models of hypertension, hypertensive
end-organ damage, and kidney disease,2–7 and studies with
ROCK inhibitors (ROCKi), such as fasudil or Y27632,
indicate protective renal actions of these compounds.4–10
Importantly, several clinical studies have also documented
beneficial effects of ROCKi in patients with cardiovascular
disorders.11,12
RhoA/ROCK are activated in the kidney and cardio-
vascular system in models of diabetes both in vitro and
in vivo.6,7,13–16 The pathway converges numerous patho-
physiological signals triggered by the diabetic milieu, and
mediates processes implicated in the pathophysiology of
nephropathy, such as upregulation of prosclerotic cytokines,
PAI-1 (plasminogen activator inhibitor 1), osteopontin, and
production of extracellular/mesangial matrix (ECM).6,7,13–17
Based on this evidence, the RhoA/ROCK pathway appears
to be a promising target for pharmacological intervention to
prevent the development and progression of nephropathy.
To address this issue, we explored the nephroprotective
potential and mechanisms of action of the ROCKi fasudil in
uninephrectomized diabetic rats with an accelerated course
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of nephropathy,18 including the effects later in the course
of this disorder. The effects of fasudil were compared with
those of the angiotensin receptor blocker (ARB) losartan, an
established treatment for both clinical and experimental DN,
and to a combination of both agents.
RESULTS
Physical and metabolic parameters
As summarized in Table 1, all diabetic groups demonstrated
lower body weight gains. The right kidney weight was
increased in diabetic animals, except the group of diabetic
rats treated with fasudil (D-FA; fasudil from Calbiochem,
San Diego, CA), and the kidney/body weight ratios were
significantly higher in all groups of diabetic rats when
compared with non-diabetic controls. Diabetic rats had
hyperglycemia and corresponding increases in HBA1c
(glycosylated hemoglobin) when compared with non-
diabetic rats (Po0.001). The metabolic parameters were
not influenced by treatment.
Blood pressure and renal functional parameters
At baseline, there were no differences in systolic blood
pressure among the groups of rats (Table 2). Systolic blood
pressure did not significantly change throughout the study in
control rats receiving vehicle (C-VE) and diabetic rats
receiving vehicle (D-VE), and in D-FA rats. In contrast,
rats treated with losartan both alone or in combination
with fasudil demonstrated lower systolic blood pressure at all
time points during follow-up, with a significant difference
at weeks 12 and 18 when compared with vehicle-treated
rats, and diabetic rats receiving fasudil as late treatment
(D-FAlate) at weeks 6 and 12.
As shown in Figure 1, 24-h urinary albumin excretion
(UalbV) was increased in D-VE rats when compared with
C-VE rats at weeks 6 and 12. Treatment with fasudil was
associated with a significant antialbuminuric effect at weeks
6 and 12, similar to the effects of losartan and the combi-
nation of both agents. However, at the end of the study, a
significant reduction in UalbV was observed only in diabetic
rats treated with losartan (D-LOS; losartan from Merck,
Whitehouse Station, NJ). Moreover, UalbV was lower in
D-LOS when compared with D-FA rats. The course of
UalbV in D-FAlate was similar to that in D-VE; UalbV
was higher than in C-VE throughout the study, and also
higher than losartan-treated animals at weeks 12 and 18
(Po0.05).
Compared with non-diabetic controls, D-VE rats demon-
strated lower glomerular filtration rate (GFR), determined as
creatinine clearance at week 18 (Figure 2). This decrease in
creatinine clearance was not observed in diabetic groups
treated with fasudil, losartan, or late fasudil; all demonstrated
significantly higher creatinine clearance values than those
observed in D-VE.
Histological analysis
The glomerular sclerosis score and proportion of severely
affected glomeruli were increased in D-VE compared
with non-diabetic controls (Figure 3). In all fasudil- and
losartan-treated groups, the glomerular sclerosis score and
proportion of severely affected glomeruli were not different
from controls, and significantly lower when compared with
D-VE rats. The tubulointerstitial fibrosis score was signif-
icantly higher in D-VE when compared with controls, and
reduced to values observed in C-VE by treatment with
fasudil, losartan, or the combination (Figure 3). Unlike the
other groups of rats, in which the treatment was initiated
at the onset of diabetes, the reduction in tubulointerstitial
fibrosis score in D-FAlate rats did not reach statistical
significance.
Determination of renal ROCK activity
Compared with C-VE, vehicle-treated diabetic rats displayed
increased phosphorylation of MYPT, a downstream substrate
Table 1 | Physical and metabolic parameters
Group BWT (g) RKW (g) RKW/BWT (g per 100g bwt) BG (mg/dl) HBA1c (%)
C-VE 460±12 2.7±0.1 0.58±0.02 72±6 3.2±0.1
D-VE 400±6w 3.3±0.1* 0.82±0.03w 295±27w 4.9±0.2w
D-FA 403±9w 3.1±0.1 0.77±0.03* 321±20w 4.9±0.2w
D-LOS 414±8* 3.4±0.2* 0.83±0.06w 327±18w 5.0±0.2w
D-FA+LOS 417±12* 3.6±0.2w 0.86±0.04w 319±25w 5.2±0.2w
D-FAlate 410±4w 3.5±0.1w 0.85±0.04w 291±29w 5.2±0.2w
Abbreviations: BG, blood glucose; BWT, body weight; C-VE, control-vehicle; D-FA, diabetic-fasudil; D-FA+LOS, diabetic-fasudil+losartan; D-FAlate, diabetic-late fasudil
treatment; D-LOS, diabetic-losartan; D-VE, diabetic-vehicle; HBA1c, glycosylated hemoglobin; RKW, right kidney weight.
*Po0.05.
wPo0.01 vs C-VE.
Table 2 | Effect of fasudil and losartan on systolic blood
pressure (mmHg)
Group Baseline Week 6 Week 12 Week 18
C-VE 135±7 133±3 141±7 147±7
D-VE 148±3 141±6 142±4 147±3
D-FA 143±6 136±6 142±6 145±8
D-LOS 146±6 127±6c 125±6*,a 127±4*,a
D-FA+LOS 145±6 127±5c 122±5*,b,c 131±4a
D-FAlate 147±6 147±5 150±4 141±6
Abbreviations: C-VE, control-vehicle; D-FA, diabetic-fasudil; D-FA+LOS, diabetic-
fasudil+losartan; D-FAlate, diabetic-late fasudil treatment; D-LOS, diabetic-losartan;
D-VE, diabetic-vehicle.
*Po0.05 vs C-VE.
aPo0.05 vs D-VE.
bPo0.01 vs D-VE.
cPo0.05 vs D-FAlate.
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of ROCKs that was analyzed as a marker of RhoA/ROCK
activity, in renal cortical homogenates (Figure 4). The phos-
phorylated myosin phosphatase target subunit 1 (P-MYT)
was barely detectable in fasudil-treated animals, indicating
effective blockade of RhoA/ROCK. In addition, a significant
reduction in phosphorylated myosin phosphatase target
subunit 1 expression was also observed in D-LOS rats.
Renal expression of mediators and markers of DN
To determine the mechanisms and possible differences in
protective effects of ROCKi and ARB in the diabetic kidney,
we next determined the effects of fasudil and losartan
on mRNA and protein expression of established mediators
and markers of DN. mRNA and protein expression studies
were performed in control and diabetic vehicle-treated rats,
and in rats with fasudil or losartan monotherapies.
As shown in Table 3, D-VE displayed increases in trans-
forming growth factor-b (TGF-b) and collagen III mRNA
expression, whereas the increases in expression of other genes
(connective tissue growth factor (CTGF), collagens I and IV,
osteopontin, and p65 nuclear factor (NF)-kB) did not reach
statistical significance. Treatment with fasudil reduced fibro-
nectin mRNA expression when compared with D-VE, but no
effects were detected on other genes. The losartan-treated
animals demonstrated lower mRNA expression of TGF-b,
fibronectin, collagens I and III mRNA, and p65 NF-kB.
The analysis of profibrotic factors and ECM proteins
at the protein level showed diabetes-induced increases in
renal abundance of TGF- b, CTGF, and fibronectin (Figure 5).
All these parameters, as well as collagen I protein, were
reduced in both fasudil- and losartan-treated rats when
compared with vehicle-treated counterparts.
Renal expression of markers associated with
epithelial–mesenchymal transition (EMT)
To further investigate the mechanisms of actions of fasudil, in
particular in the tubulointerstitial compartment, we deter-
mined expression of the EMT markers, fibroblast-specific
protein 1 (FSP1, also known as S100A4), a-smooth muscle
actin (a-SMA), vimentin, and E-cadherin. Screening renal
cortical samples revealed marked upregulation of mRNA for
the early marker FSP119 in diabetic animals (Table 3), which
was reduced in D-FA and D-LOS rats. In C-VE, immuno-
histochemical analysis localized FSP1 in occasional interstitial
and tubular cells. In contrast, D-VE rats demonstrated
massive accumulations of FSP1-positive cells in the cortical
interstitium (Figure 6), frequently associated with areas of
tubular atrophy and surrounding fibrosis. The FSP1 inter-
stitial immunoreactivity was also detected in D-FA and
D-LOS rats, but only in small clusters or single cells. a-SMA
was detected in vascular structures in all groups, whereas
tubulointerstitial immunoreactivity was detectable in D-VE
rats (Figure 6), to a lesser extent in D-FA rats, and practically
undetectable in C-VE and D-LOS animals. In addition
to glomerular localization of vimentin, observed in all
groups of rats, D-VE displayed abundant tubulointerstitial
vimentin immunoreactivity, which was reduced in both
fasudil- and losartan-treated diabetic kidneys (Figure 6).
E-cadherin was localized predominantly in distal tubules
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Figure 1 | The 24h urinary albumin excretion. Non-diabetic and diabetic rats receiving vehicle (C-VE, D-VE), and diabetic rats treated
with fasudil (D-FA), losartan (D-LOS), a combination of fasudil and losartan (D-FAþ LOS), or fasudil as late treatment initiated 12 weeks
after induction of diabetes (D-FAlate) underwent measurements of 24-h urinary albumin excretion in metabolic cages at weeks 6, 12,
and 18. The data are expressed as geometric means  /C tolerance factor. *Po0.05 vs C-VE; aPo0.05 vs D-VE; bPo0.05 vs D-LOS and
D-FAþ LOS; cPo0.05 vs D-LOS; dPo0.05 vs D-FA.
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Figure 2 |The 24h creatinine clearance (CCr). Non-diabetic and
diabetic rats receiving vehicle (C-VE, D-VE), and diabetic rats
treated with fasudil (D-FA), losartan (D-LOS), a combination of
fasudil and losartan (D-FAþ LOS), or fasudil as late treatment
initiated 12 weeks after induction of diabetes (D-FAlate)
underwent measurements of CCr in metabolic cages at week 18.
*Po0.05; aPo0.05 vs D-VE.
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in all groups of rats without apparent effects of diabetes or
treatments.
The immunohistochemical findings were mirrored by
measurements of protein abundance of EMT markers by
immunoblotting (Figure 7) indicating increases in FSP1, a-
SMA, and vimentin in D-VE when compared with non-
diabetic animals, and reductions in rats receiving fasudil or
losartan treatments. In contrast, there were no significant
differences in E-cadherin expression between the groups
of rats.
Renal expression of nephrin and vascular endothelial growth
factor (VEGF)
Further analyses determined renal cortical expression of
nephrin and VEGF, the important determinants of glomer-
ular filtration barrier.20–22 The mRNA expression of the
podocyte protein nephrin was decreased in D-VE compared
with non-diabetic animals, and restored by fasudil and
partially by losartan (Figure 8a). Although this diabetes-
induced nephrin downregulation was not observed at the
protein level, fasudil-treated rats demonstrated increased
nephrin protein abundance when compared with both
diabetic and non-diabetic controls (Figure 8b). Unlike
nephrin, VEGF protein expression was similar among the
groups (Figure 8c).
DISCUSSION
In the present studies, uninephrectomized diabetic rats
displayed a more rapid course in the development of
albuminuria, reduction in GFR, and progressive glomerulo-
sclerosis and interstitial fibrosis when compared with non-
diabetic uninephrectomized animals. Treatment with the
ROCKi fasudil, when initiated at the onset of diabetes, was
nephroprotective as assessed by its effects on a spectrum of
structural, functional, and molecular characteristics of DN.
These beneficial effects were observed despite the absence
of an effect on blood pressure, in accord with previous
evidence in non-diabetic models of hypertensive end-organ
injury2,4,5,8,9,23 and in models of DN.7 The diabetes-induced
increase in MYPT phosphorylation, measured as a marker of
RhoA/ROCK activation, was suppressed by fasudil, indicating
effective inhibition of the pathway.
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Figure 3 |Analysis of glomerular sclerosis score (GSS), proportion of severely affected glomeruli, and tubulointerstitial fibrosis
score (TIFS). (a) Representative microphotographs of glomeruli stained with periodic acid Schiff (PAS) with different degrees of
glomerulosclerosis and (b) interstitial regions stained with trichrome showing areas of various degrees of interstitial fibrosis and tubular
atrophy. (c) Bar graph presentation of quantitative evaluation of GSS, (d) proportion of severely affected glomeruli, and (e) TIFS.
C-VE, control-vehicle; D-FA, diabetic-fasudil; D-FAþ LOS, diabetic-fasudilþ losartan; D-FAlate, diabetic-late fasudil treatment; D-LOS,
diabetic-losartan; D-VE, diabetic-vehicle. wPo0.01 vs C-VE; aPo0.05; bPo0.01 vs D-VE.
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Studies exploring the long-term effects of ROCKi in
models of DN have only recently started to emerge.
Nephroprotective effects of fasudil have been explored
in earlier stages of nephropathy in streptozotocin-diabetic
rats7 and in db/db mice,6 a model of type 2 diabetes mellitus.
Both studies documented beneficial effects of fasudil on
the development of mesangial expansion, proteinuria, and
expression of ECM proteins, associated with reductions of
diabetes-induced increases in RhoA/ROCK activity.
Our observations are in accord with the above-mentioned
studies, and also extend the evidence in several directions
that have not been previously explored in models of type 1
diabetes: evaluation of ROCKi in more advanced stages of
nephropathy; evaluation of ROCKi in combination with RAS
inhibition; and evaluation of the effects of ROCKi initiated
later in the course of the disease. In addition to the effects on
glomerular architecture, this design allowed us to document
beneficial effects of fasudil on tubulointerstitial fibrosis, and
preservation of renal function to levels comparable to those
in non-diabetic animals. It should be noted that a similar
design has been previously applied in a study exploring the
effects of fasudil in OLETF (Otsuka Long-Evans Tokushima
fatty) rats,24 a model of type 2 diabetes. However, in that
study the renoprotective effects of fasudil (100mg/kg) were
associated with amelioration of diabetes and could be
therefore attributable to improved metabolic status rather
than a more direct effect of the drug.
In parallel with the beneficial effects on renal architecture,
we observed beneficial effects of fasudil on albuminuria at
weeks 6 and 12, although the effect was not apparent at the
end of the study. Notably, the UalbV plateaued in D-VE rats at
the end of the follow-up, most likely because of the
decreasing GFR, as some of these animals displayed lower
UalbV at week 18 compared with week 12, and to increased
albuminuria over time in C-VE animals. This decrease in
GFR in D-VE rats is attributable to both more advanced
glomerulosclerosis and tubulointerstitial sclerosis, which is
an important determinant of GFR at later stages of chronic
kidney disease.25
The effects of fasudil were compared with the ARB
losartan, a compound with established nephroprotective
effects in both clinical26 and experimental27 settings. The
structural effects of fasudil were comparable to those of
losartan. However, losartan appeared to be more effective in
reducing albuminuria, especially at the end of the study. The
more prominent effects of losartan on albuminuria are most
likely attributable to its effects on blood pressure, an
important driving force for proteinuria.
Strategies that might enhance the therapeutic efficacy of
RAS inhibitors are likely to have an important impact on
nephroprotection in diabetes. Studies have suggested possible
synergism in high glucose- and angiotensin II (AngII)-
induced RhoA/ROCK signaling in mesangial cells,28 attenua-
tion of glomerular microvascular actions of AngII by
ROCKi,29,30 and beneficial effects of ROCKi on AngII- and
aldosterone-induced renal injury.4,10 Therefore, we hypothe-
sized that the combination of ROCKi and ARB could
enhance the beneficial effects of the monotherapies. However,
we detected no further protective effect of fasudil when
combined with losartan. This phenomenon corresponds to
another observation in the present study, the significant
reduction in MYPT phosphorylation in losartan-treated rats,
suggesting that AngII inhibition might interfere with RhoA/
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Figure 4 |Renal protein expression of phosphorylated and
total MYPT. MYPT phosphorylation (Thr853) was determined
in conjunction with total MYPT protein by western blotting as
an indicator of renal Rho-associated kinase (ROCK) activity.
Data are presented as protein/actin ratios plotted on y axis.
The upper panel shows representative blots. C-VE, control-vehicle;
D-FA, diabetic-fasudil; D-LOS, diabetic-losartan; D-VE, diabetic-vehicle.
*Po0.05 vs C-VE; aPo0.01 vs D-VE.
Table 3 | Gene expression of mediators and markers of
diabetic nephropathy
Genes C-VE D-VE D-FA D-LOS
n 8 8 8 7
TGF-b 1.0±0.2 1.8±0.4* 1.8±0.6 0.7±0.2a,c
CTGF 1.0±0.2 2.4±0.4 1.75±0.3 2.0±0.4
Fibronectin 1.0±0.1 0.8±0.3 0.3±0.1* 0.3±0.1*
Collagen I 1.0±0.3 2.1±0.65 3.7±0.5w 0.8±0.2c
Collagen III 1.0±0.3 2.6±0.3* 3.0±0.4* 1.0±0.2a,c
Collagen IVa3 1.0±0.2 2.0±0.6 1.0±0.2 1.0±0.3
Osteopontin 1.0±0.2 3.5±1.5 3.4±0.4 1.4±0.4
P65 NFkappaB 1.0±0.3 1.9±0.7 2.2±0.5 0.7±0.1a
FSP1 1.0±0.2 27.0±9.4* 2.5±0.6b 1.6±0.5b
Abbreviations: CTGF, connective tissue growth factor; C-VE, control-vehicle; D-FA,
diabetic-fasudil; D-LOS, diabetic-losartan; D-VE, diabetic-vehicle; FSP1, fibroblast-
specific protein 1; TGF-b, transforming growth factor-b.
The data are expressed as fold induction compared with C-VE.
*Po0.05.
wPo0.01 vs C-VE.
aPo0.05 vs D-VE.
bPo0.01 vs D-VE.
cPo0.05 vs D-FA.
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ROCK signaling. Interestingly, a similar, although not
significant, phenomenon was reported in rats treated with
enalapril.7 Another mechanism explaining this phenomenon
has been suggested by Savoia et al.,31 who demonstrated that
stimulation of AngII AT2 receptors could lead to ROCK
inhibition. Indeed, enhanced activation of the AT2 receptor
could be expected during losartan treatment because of
increased availability of AngII to stimulate this receptor
subtype.
On the other hand, it should be stressed that the RAS
inhibitors are usually so effective in rodent models of DN
that it is difficult to detect additive effects of combination
treatments. We cannot exclude the possibility that in a
different model or, clinically, the combination of ROCKi with
ARB might be proven more beneficial than ARB mono-
therapy.
In clinical diabetes, treatment is most often initiated in
patients who have already developed evidence of nephro-
pathy. Therefore, we also evaluated the effects of starting
fasudil after 12 weeks without treatment. In these animals, we
still detected beneficial effects on glomerular lesions and
GFR, but treatment did not significantly influence the
tubulointerstitial fibrosis score, and completely lacked
antiproteinuric efficacy. During the course of nephropathy,
the lesions in individual glomeruli develop at a variable rate.
After 12 weeks of diabetes, uninephrectomized rats display
lesions spanning from normal to completely sclerotic
glomeruli. Based on recent observations by Teles et al.,27
who have described long-term dynamics in the development
of glomerulosclerosis in diabetic rats, the partial protection
observed after delayed fasudil may be attributable to its
effects on normal or mildly affected glomeruli. However, the
treatment did not reverse established glomerular lesions and
interstitial fibrosis.
To identify the molecular basis of fasudil’s observed effects
and possible differences between the actions of fasudil and
those of losartan, we further investigated mRNA and protein
expression of a spectrum of markers and mediators known to
be upregulated at various stages of DN.32–35 We detected
diabetes-induced expression of TGF-b and collagen III
mRNA. Treatment with fasudil reduced renal fibronectin
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Figure 5 |Renal cortical protein expression of transforming
growth factor-b (TGF-b), connective tissue growth factor
(CTGF), fibronectin (FN), and collagen I. Protein expression was
analyzed by western blotting in renal cortical homogenates.
The graphs show densitometric analysis of western blots.
The insets show representative blots of C-VE, non-diabetic animals
(lanes 1 and 2); D-VE, the vehicle-treated diabetic rats (lanes 3 and
4); D-FA, fasudil-treated diabetic animals (lanes 5 and 6); and
D-LOS, losartan-treated diabetic animals (lanes 7 and 8). Fasudil
and losartan were both effective in reducing diabetes-induced
increases in renal TGF-b (a), CTGF (b), and FN expression (c), and
reduced abundance of collagen I (d). Data are presented as
protein/actin ratios. C-VE, control-vehicle; D-FA, diabetic-fasudil;
D-LOS, diabetic-losartan; D-VE, diabetic-vehicle. *Po0.05, wPo0.01
vs C-VE; aPo0.05, bPo0.01 vs D-VE.
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mRNA expression, whereas losartan seemed to be more
effective on the mRNA expression of TGF-b, fibronectin,
collagens I and III mRNA, and p65 NF-kB gene expression.
At the protein level, both treatments were effective in
reducing TGF-b, CTGF, fibronectin, and collagen I protein
abundance. These reductions in ECM protein abundances
are in accord with recently published long-term effects of
fasudil in DN,6,7 whereas fasudil-induced suppression of
TGF-b and CTGF expression corresponds to findings
in models of non-diabetic progressive glomerulosclerosis
and interstitial fibrosis.4,9,10
Both TGF-b and CTGF stimulate EMT,36,37 a process
closely linked with the development of renal fibrosis.
Although the role of EMT in mediating renal fibrosis in
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Figure 6 | Immunohistochemical expression and localization of markers associated with epithelial–mesenchymal transition (EMT)
in renal cortex. Representative microphotographs ( 200) show cortical sections from non-diabetic animals (C-VE), vehicle-treated
diabetic rats (D-VE), fasudil-treated diabetic animals (D-FA), and diabetic animals treated with losartan (D-LOS) probed with primary
antibodies raised against fibroblast-specific protein 1 (FSP1), a-smooth muscle actin (a-SMA), vimentin, and E-cadherin. Images of
sections stained with nonimmune serum are shown for D-VE rats (D-VEni). Arrows show tubulointerstitial and arrowheads show vascular
immunoreactivity of proteins of interest.
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diabetes is still debated, particularly in vivo, there is
increasing evidence supporting a role for this process.38–40
The Rho/ROCK pathway has been shown to mediate EMT
in a non-diabetic context.41,42 Consequently, we next studied
EMT indicators. The data show that uninephrectomized
diabetic rats display markers of EMT, such as FSP1, a-SMA,
and vimentin. The expression of these markers was
attenuated by ROCKi in conjunction with beneficial effects
on renal fibrosis and reduced expression of TGF-b and CTGF.
Fasudil reduced EMT to an extent similar to that of losartan.
The effect of losartan is in accord with described role of
AngII in stimulating EMT in vitro,42–44 and validates those
observations in vivo.
Loss of E-cadherin, a phenomenon traditionally associated
with EMT,45 was not detected in diabetic kidneys. This
finding corresponds to the recently described partial EMT
phenotype,46 and emerging evidence that this process might
operate in the diabetic kidney.47 It has been postulated
that the entire classical EMT program observed primarily
in vitro, with the associated decrease in E-cadherin, may not
be critical for the development and progression of tubuloin-
terstitial fibrosis.47 Both TGF-b and CTGF increase ECM
expression independently of E-cadherin. TGF-b lowers
E-cadherin, whereas CTGF (a driver of partial EMT) increases
E-cadherin expression. Moreover, an increase in E-cadherin
has been recently reported in rats with ureteral obstruction,
a classical model of EMT-mediated kidney fibrosis.48
The blood pressure-independent antiproteinuric effect of
fasudil suggests beneficial actions on the glomerular filtration
barrier. In this context, we investigated the impact of this
treatment on nephrin expression. Although loss of nephrin in
glomerular epithelial cells is associated with severe protei-
nuria, studies in experimental diabetes have produced
conflicting data showing decreased,20 unchanged,22 or
increased49 glomerular nephrin mRNA and protein. In the
present study, kidneys from D-VE rats displayed marked
reductions in nephrin mRNA, which were restored by fasudil
and partially by treatment with losartan. The diabetes-
induced downregulation of nephrin was not observed at
the protein level; however, similar to the effects on mRNA,
both fasudil and losartan increased nephrin renal cortical
protein abundance. This suggests that modulation of
nephrin expression might be associated with the modest
antiproteinuric effects of fasudil, a phenomenon correspond-
ing to recently reported beneficial effects of this compound
on effacement of foot processes.7 Furthermore, we observed
no effect of diabetes and treatments on renal VEGF
protein expression. Although VEGF may be elevated in
the initial phases of DN,50 our finding most likely reflects
more advanced stage of DN, when this increase may not
be maintained as chronic fibrotic changes occur in the
kidney.51,52
Some differences between the groups in molecular
markers and mediators of nephropathy were more prominent
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Figure 7 | Immunoblot analysis of markers associated with epithelial–mesenchymal transition (EMT) in renal cortex. Protein
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at the protein rather than the mRNA level. Although this
phenomenon could be attributable to diabetes-induced
impairment in protein degradation,53 mRNA activation
earlier in the course of the disease, or the influence of
uninephrectomy driving the expression of pro-growth
genes also in non-diabetic kidneys,54 it also suggests post-
transcriptional mechanisms. Indeed, this notion is supported
by analysis of p70S6K (phosphorylation of the 70-kD S6
protein kinase) and 4E-BP1 (eIF4E-binding protein-1), the
pivotal intermediates in a process of initiation of mRNA
translation,55 which suggests increased activity of this
pathway in the diabetic kidney and its amelioration by
fasudil or losartan (Supplementary Figure 1 online). Of note,
activation of mRNA translation has been previously
implicated in enhanced ECM synthesis in the diabetic
kidney,56–58 and represents a promising target for future
studies in this field of ROCK pathobiochemistry in diabetes.
In conclusion, ROCKi with fasudil initiated at the onset of
diabetes had blood pressure-independent beneficial effects on
the development of glomerulosclerosis and interstitial fibrosis
in uninephrectomized diabetic rats, associated with a modest
antiproteinuric effect. These beneficial structural effects
were comparable to those of the ARB losartan, and were
associated with reduced expression of prosclerotic cyto-
kines and ECM proteins, partial suppression of the EMT
phenotype, and upregulation of nephrin. However, the
study did not document additive beneficial effects
of combination ROCKi/ARB when compared with ARB
monotherapy.
MATERIALS AND METHODS
The diabetic rat model
Male Sprague-Dawley rats were subjected to right nephrectomy
under Brevital anesthesia (50mg/kg intraperitoneal) at the age of
8 weeks. After 2 weeks, some rats were made diabetic by intra-
peritoneal injection of streptozotocin (Sigma Chemical, St Louis,
MO; 55mg per kg body weight). The uninephrectomized diabetic
rat model was employed to accelerate the development of renal
injury.18 After 2 days, induction of diabetes was confirmed by
measurement of tail blood glucose level (One Touch II; Lifescan,
Milpitas, CA). Diabetic rats received daily evening injections of
long-acting glargine insulin (Lantus; Eli Lilly, Indianapolis, IN)
in doses individually adjusted to maintain blood glucose at
B300mg/dl (17mmol/l). Blood glucose levels were monitored at
least weekly in all diabetic rats. Uninephrectomized rats injected
with phosphate buffer were studied as non-diabetic controls. These
studies were approved by the Portland VA institutional animal care
and use subcommittee.
Study design
After confirmation of hyperglycemia in diabetic rats, the animals
were randomized into the following groups: (1) C-VE (tap water)
(n¼ 9); (2) D-VE (n¼ 10); (3) D-FA (Calbiochem; fasudil
30mg/kg/day;23 n¼ 10); (4) D-LOS (Merck; losartan 20mg/kg/
day;59 n¼ 10); (5) diabetic rats receiving both fasudil and losartan
(n¼ 10, D-FAþ LOS); and (6) diabetic rats receiving fasudil as
late treatment initiated 12 weeks after induction of diabetes (n¼ 11,
D-FAlate). All drugs were administered in the drinking water.
The rats were maintained on these treatments for 18 weeks,
except the D-FAlate rats that received fasudil for 6 weeks.
Measurements of systolic blood pressure (tail plethysmography),
blood glucose, and UalbV were performed at weeks 6, 12, and 18.
Plasma levels and urinary creatinine excretion rates allowing
calculation of 24-h creatinine clearance were measured at week 18.
Within 2 to 3 days after the last urinary collection, the animals were
anesthetized with Inactin (100mg/kg intraperitoneal) and blood
samples were obtained for determination of HBA1c. The left kidney
was then harvested for morphological studies and molecular
analyses.
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Figure 8 |Renal cortical expression of nephrin and vascular
endothelial growth factor (VEGF). Nephrin gene expression
(a) was analyzed in renal cortical samples by real-time PCR (rtPCR).
The data are shown as fold induction compared with C-VE. Protein
expression was analyzed by western blotting in renal cortical
homogenates. (b) Densitometric analysis and representative
images of nephrin western blots. Data are presented as protein/
actin ratios plotted on y axis. (c) Representative images for
VEGF western blots (C-VE, non-diabetic animals (lanes 1 and 2);
D-VE, the vehicle-treated diabetic rats (lanes 3 and 4); D-FA,
fasudil-treated diabetic animals (lanes 5 and 6); and D-LOS,
losartan-treated diabetic animals (lanes 7 and 8)). *Po0.05 vs
C-VE; aPo0.05 vs D-VE.
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Glomerulosclerosis score
The excised kidneys were immersed in 10% formalin, then
dehydrated through a graded series of ethanols, embedded in
paraffin, sectioned at 4 mm thickness, and placed onto glass slides.
The glomerular sclerosis score was determined on periodic acid
Schiff-stained sections using a scale ranging from 0 to 4 for normal
(0), 1¼ 25% sclerosis, 2¼ 50% sclerosis, 3¼ 75% sclerosis, and
4¼ 100% sclerosis as previously described.60 On average, 200
glomeruli were evaluated per rat. In addition to traditional scoring,
the proportion of glomeruli with advanced glomerulosclerotic
lesions characterized by confluent areas of dense deposition of
periodic acid Schiff-positive material at the glomerular tuft,
capillary loop occlusions, and adhesions of the glomerular tuft to
Bowman’s capsule was determined for each kidney section.
Tubulointerstitial fibrosis score
Measurements were performed on Masson-trichrome-stained
sections. The 100 square grid was applied at low magnification
( 50) on consecutive microscopic cortical fields starting at
renal hili in a clockwise direction. The number of squares
containing stained fibrous tissue or atrophic tubules was recorded
for each field and averaged for each kidney. Perivascular spaces
and glomeruli were not counted. On average, 18 fields were
evaluated per kidney. All structural analyses were conducted in
a blind manner.
Isolation of total RNA, synthesis of cDNA, and quantitative
real-time PCR
These methods were performed as previously published61 and
detailed in Supplementary Material. The primer sequences are listed
in Supplementary Table 1 online.
Immunoblotting
Western blot analysis was performed as previously described.62,63
The description and list of primary antibodies are provided in
Supplementary Material.
Immunohistochemistry
For immunohistochemical analysis, the formalin-fixed, paraffin-
embedded kidneys were processed as previously described.62
More detailed information is provided in Supplementary Material.
Analytical methods
Urinary albumin concentrations were determined using the
Nephrat kit (Exocell, Philadelphia, PA). Serum and urine creatinine
concentrations were measured by spectrophotometric assay
(Biovision, Mountain View, CA). HBA1c was determined by
affinity column chromatography (Glyco-Gel B; Pierce Chemical,
Rockford, IL).
Statistical analysis
Comparisons of variables between control and diabetic groups
were analyzed by one-way analysis of variance followed by the
Bonferoni test. Statistical significance was defined as Po0.05.
Data were expressed as means±s.e.m. Data for albuminuria were
analyzed after logarithmic transformation and the data expressed as
geometric means  /C tolerance factor.
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